
The episode discusses the POET trial and the implications of early oral antibiotic switch therapy for endocarditis.
In this episode of Communicable , Emily McDonald and Josh Davis host Henning Bundgaard and Sami El-Dalati for a discussion on early oral antibiotic switch for endocarditis, focusing on the POET trial, led by Bundgaard, and its clinical impact seven years after the results were first published in 2019 [1]. The episode also covers the ‘prose’ and cons of early oral switch therapy, as well as broader challenges of implementing new evidence in practice when it goes against long-standing dogma. References Iversen K, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis, NEJM 2018. DOI: 10.1056/NEJMoa1808312 Further reading: Pries-Heje MM, et al. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial, NEJM 2022. DOI: 10.1056/NEJMc2114046 El-Dalati S, et al. Partial Oral Versus Intravenous Antibiotic Therapy for Endocarditis With Management by a Multidisciplinary Team: A Retrospective Cohort Study, OFID 2025. DOI: 10.1093/ofid/ofaf625 McDonald EM, et al. Guidelines for Diagnosis and Management of Infective Endocarditis in Adults: A WikiGuidelines Group Consensus Statement, JAMA Netw Open 2023. DOI: 10.1001/jamanetworkopen.2023.26366 European…
Hosts: Emily McDonald, Josh Davis
Guests: Henning Bundgaard, Sami El-Dalati
Organizations: CMI Communications, European Society of Cardiology
Books & works: Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis, Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial, Partial Oral Versus Intravenous Antibiotic Therapy for Endocarditis With Management by a Multidisciplinary Team: A Retrospective Cohort Study, Guidelines for Diagnosis and Management of Infective Endocarditis in Adults: A WikiGuidelines Group Consensus Statement
Explore listener stats, chart rankings, contacts and more on the Communicable podcast page.